BiogenBIIBEarnings & Financial Report
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
BIIB Q1 FY2026 Key Financial Metrics
Revenue
$2.5B
Gross Profit
N/A
Operating Profit
N/A
Net Profit
$319.5M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
12.9%
YoY Growth
2.0%
EPS
$2.15
Biogen Q1 FY2026 Financial Summary
Biogen reported revenue of $2.5B (up 2.0% YoY) for Q1 FY2026, with a net profit of $319.5M (up 32.8% YoY) (12.9% margin).
Key Financial Metrics
| Total Revenue | $2.5B |
|---|---|
| Net Profit | $319.5M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q1 FY2026 |
Revenue Breakdown
Biogen Q1 FY2026 revenue of $2.5B breaks down across 6 segments, led by Product revenue, net at $1.8B (70.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Product revenue, net | $1.8B | 70.7% |
| Royalty revenue on sales of OCREVUS | $317.2M | 12.8% |
| Contract manufacturing, royalty and other revenue | $246.9M | 10.0% |
| Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO | $94.7M | 3.8% |
| Alzheimer's collaboration Revenue | $59.5M | 2.4% |
| Other revenue from anti-CD20 therapeutic programs | $7.2M | 0.3% |
Biogen Annual Revenue by Year
Biogen annual revenue history includes year-by-year totals (for example, 2025 revenue was $9.9B).
Biogen Quarterly Revenue & Net Profit History
Biogen results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $2.5B | +2.0% | $319.5M | 12.9% |
| Q4 FY2025 | $2.3B | -7.1% | $-48.9M | -2.1% |
| Q3 FY2025 | $2.5B | +2.8% | $466.5M | 18.4% |
| Q2 FY2025 | $2.6B | +7.3% | $634.8M | 24.0% |
| Q1 FY2025 | $2.4B | +6.1% | $240.5M | 9.9% |
| Q4 FY2024 | $2.5B | +2.9% | $266.7M | 10.9% |
| Q3 FY2024 | $2.5B | -2.5% | $388.5M | 15.8% |
| Q2 FY2024 | $2.5B | +0.4% | $583.6M | 23.7% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.46B | $2.47B | $2.45B | $2.43B | $2.65B | $2.53B | $2.28B | $2.48B |
| YoY Growth | 0.4% | -2.5% | 2.9% | 6.1% | 7.3% | 2.8% | -7.1% | 2.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $26.80B | $28.31B | $28.05B | $28.03B | $28.33B | $29.21B | $29.44B | $29.48B |
| Liabilities | $10.91B | $11.95B | $11.33B | $11.05B | $10.70B | $11.00B | $11.18B | $10.83B |
| Equity | $15.89B | $16.36B | $16.72B | $16.98B | $17.63B | $18.21B | $18.26B | $18.65B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $625.8M | $935.6M | $760.9M | $259.3M | $160.9M | $1.27B | $511.9M |